These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 18410895)

  • 1. Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors.
    Furlong T; Kiem HP; Appelbaum FR; Carpenter PA; Deeg HJ; Doney K; Flowers ME; Mielcarek M; Nash RA; Storb R; Martin PJ
    Biol Blood Marrow Transplant; 2008 May; 14(5):531-7. PubMed ID: 18410895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirolimus and tacrolimus as immune prophylaxis compared to cyclosporine with or without methotrexate in patients undergoing allogeneic haematopoietic stem cell transplantation for non-malignant disorders.
    Ringdén O; Remberger M; Dahllöf G; Garming-Legert K; Karlsson H; Svenberg P; Uhlin M; Uzunel M; Mattsson J
    Eur J Haematol; 2011 Dec; 87(6):503-9. PubMed ID: 22974354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate.
    Perez-Simón JA; Martino R; Parody R; Cabrero M; Lopez-Corral L; Valcarcel D; Martinez C; Solano C; Vazquez L; Márquez-Malaver FJ; Sierra J; Caballero D
    Haematologica; 2013 Apr; 98(4):526-32. PubMed ID: 23065527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.
    Cutler C; Kim HT; Hochberg E; Ho V; Alyea E; Lee SJ; Fisher DC; Miklos D; Levin J; Sonis S; Soiffer RJ; Antin JH
    Biol Blood Marrow Transplant; 2004 May; 10(5):328-36. PubMed ID: 15111932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors.
    Nash RA; Antin JH; Karanes C; Fay JW; Avalos BR; Yeager AM; Przepiorka D; Davies S; Petersen FB; Bartels P; Buell D; Fitzsimmons W; Anasetti C; Storb R; Ratanatharathorn V
    Blood; 2000 Sep; 96(6):2062-8. PubMed ID: 10979948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
    Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.
    Ratanatharathorn V; Nash RA; Przepiorka D; Devine SM; Klein JL; Weisdorf D; Fay JW; Nademanee A; Antin JH; Christiansen NP; van der Jagt R; Herzig RH; Litzow MR; Wolff SN; Longo WL; Petersen FB; Karanes C; Avalos B; Storb R; Buell DN; Maher RM; Fitzsimmons WE; Wingard JR
    Blood; 1998 Oct; 92(7):2303-14. PubMed ID: 9746768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of tacrolimus and cyclosporine combined with methotrexate for graft-versus-host disease prophylaxis, stratified by stem cell source: a retrospective nationwide survey.
    Sakai R; Taguri M; Oshima K; Mori T; Ago H; Adachi S; Morita S; Taniguchi S; Fukuda T; Ohashi K; Eto T; Miyamura K; Iwato K; Kobayashi N; Kanamori H; Morishima Y; Nagamura-Inoue T; Sakamaki H; Atsuta Y; Murata M
    Int J Hematol; 2016 Mar; 103(3):322-33. PubMed ID: 26800676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation.
    Törlén J; Ringdén O; Garming-Legert K; Ljungman P; Winiarski J; Remes K; Itälä-Remes M; Remberger M; Mattsson J
    Haematologica; 2016 Nov; 101(11):1417-1425. PubMed ID: 27662016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.
    Cutler C; Logan B; Nakamura R; Johnston L; Choi S; Porter D; Hogan WJ; Pasquini M; MacMillan ML; Hsu JW; Waller EK; Grupp S; McCarthy P; Wu J; Hu ZH; Carter SL; Horowitz MM; Antin JH
    Blood; 2014 Aug; 124(8):1372-7. PubMed ID: 24982504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation.
    Antin JH; Kim HT; Cutler C; Ho VT; Lee SJ; Miklos DB; Hochberg EP; Wu CJ; Alyea EP; Soiffer RJ
    Blood; 2003 Sep; 102(5):1601-5. PubMed ID: 12730113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.
    Labrador J; López-Corral L; López-Godino O; Vázquez L; Cabrero-Calvo M; Pérez-López R; Díez-Campelo M; Sánchez-Guijo F; Pérez-López E; Guerrero C; Alberca I; Del Cañizo MC; Pérez-Simón JA; González-Porras JR; Caballero D
    Bone Marrow Transplant; 2014 May; 49(5):684-90. PubMed ID: 24566710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation.
    Pidala J; Kim J; Jim H; Kharfan-Dabaja MA; Nishihori T; Fernandez HF; Tomblyn M; Perez L; Perkins J; Xu M; Janssen WE; Veerapathran A; Betts BC; Locke FL; Ayala E; Field T; Ochoa L; Alsina M; Anasetti C
    Haematologica; 2012 Dec; 97(12):1882-9. PubMed ID: 22689677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal assessment of morbidity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation: retrospective analysis of a multicenter phase III study.
    Carnevale-Schianca F; Leisenring W; Martin PJ; Furlong T; Schoch G; Anasetti C; Appelbaum FR; Carpenter PA; Deeg HJ; Kiem HP; Storb R; McDonald GB; Nash RA
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):749-56. PubMed ID: 19450760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.
    Chhabra S; Liu Y; Hemmer MT; Costa L; Pidala JA; Couriel DR; Alousi AM; Majhail NS; Stuart RK; Kim D; Ringden O; Urbano-Ispizua A; Saad A; Savani BN; Cooper B; Marks DI; Socie G; Schouten HC; Schoemans H; Abdel-Azim H; Yared J; Cahn JY; Wagner J; Antin JH; Verdonck LF; Lehmann L; Aljurf MD; MacMillan ML; Litzow MR; Solh MM; Qayed M; Hematti P; Kamble RT; Vij R; Hayashi RJ; Gale RP; Martino R; Seo S; Hashmi SK; Nishihori T; Teshima T; Gergis U; Inamoto Y; Spellman SR; Arora M; Hamilton BK
    Biol Blood Marrow Transplant; 2019 Jan; 25(1):73-85. PubMed ID: 30153491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells.
    Inamoto Y; Flowers ME; Appelbaum FR; Carpenter PA; Deeg HJ; Furlong T; Kiem HP; Mielcarek M; Nash RA; Storb RF; Witherspoon RP; Storer BE; Martin PJ
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):1088-92. PubMed ID: 21421070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
    Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation.
    Cutler C; Li S; Ho VT; Koreth J; Alyea E; Soiffer RJ; Antin JH
    Blood; 2007 Apr; 109(7):3108-14. PubMed ID: 17138818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Tacrolimus and Cyclosporine Combined With Methotrexate for Graft Versus Host Disease Prophylaxis After Allogeneic Hematopoietic Cell Transplantation.
    Huang B; Lin X; Zhang Z; Zhang Y; Zheng Z; Zhong C; He X; Chen M
    Transplantation; 2020 Feb; 104(2):428-436. PubMed ID: 31283681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.